30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Episurf Reports 2Q19 Revenue of SEK 1.1MM (USD $0.1MM), +37.5% vs. 2Q18 -



  • Gross order intake for the quarter increased 21% year over year.
  • Orders for the Episealer knee implant increased 14% vs. prior year, with 49 orders.
  • U.S. patient recruitment for the EPIC Knee study is ready to commence.
  • The company received patent approvals in the U.S., Japan and Europe
  • Entered into an agreement with a U.S.-based orthopedic company for use of Episurf’s AI-based imaging tool Epioscopy in allograft surgeries. Details and financial considerations of the agreement are currently confidential.


Segment sales and growth on an as-reported basis is as follows ($MM).

  2Q19 2Q18 $ Chg % Chg
Joint Replacement, Knees $0.1 $0.1 $0.0 37.5%
  1H19 1H18 $ Chg % Chg
Joint Replacement, Knees $0.3 $0.2 $0.1 32.8%


Sources: Episurf

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.